{"id":24691,"date":"2022-09-19T20:17:39","date_gmt":"2022-09-20T00:17:39","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&p=24691"},"modified":"2025-01-13T14:36:04","modified_gmt":"2025-01-13T19:36:04","slug":"dmitriy-zamarin-md-phd","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/dmitriy-zamarin-md-phd","title":{"rendered":"Dmitriy Zamarin, MD, PhD"},"content":{"rendered":"\n

Dr. Dmitriy Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center. He is the study chair of the clinical trial \u201cA Phase 1\/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies\u201d (NCT02963831<\/a>).<\/p>\n\n\n\n

Ovarian cancer<\/a> and colorectal cancer<\/a> are two types of cancer for which better treatments are urgently needed.<\/p>\n\n\n\n

Ovarian cancer impacts 300,000 women globally each year, with 180,000 resulting deaths, making ovarian cancer the leading cause of death from gynecologic cancer. The United States saw 22,000 cases and 14,000 deaths in 2018 alone. Ovarian cancer can progress significantly before a patient is diagnosed as early symptoms can be easily confused with less life-threatening digestive issues. As such, only 20% of ovarian cancers are detected before they metastasize.<\/p>\n\n\n\n

Colorectal cancer is the third most common cancer type and the second deadliest in the United States. Globally, there are approximately 1.8 million cases diagnosed each year, along with over 900,000 resulting deaths. In the United States alone, there were approximately 150,000 new cases and 52,000 colorectal cancer-related deaths in 2019, making colorectal cancer the third most common cancer and the second deadliest in the country. The underuse of preventative and early-stage screening results in 60% of all colorectal cancers being detected at an advanced stage, which makes it harder to treat.<\/p>\n\n\n\n

This trial studies the safety and effectiveness of a checkpoint immunotherapy<\/a> plus an oncolytic virus<\/a> in patients with advanced ovarian or colorectal cancer that is resistant to platinum-based chemotherapy. The checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the virus (ONCOS-102) can both kill cancer cells and alert the immune system to the cancer\u2019s presence.<\/p>\n\n\n\n

Additional investigators working on this trial include:<\/p>\n\n\n\n